Belvedere Trading
CLRB icon

Belvedere Trading’s Cellectar Biosciences CLRB Stock Holding History

Belvedere Trading’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-840
Closed -$100K – 728
2024
Q1 		$100K Buy
+840
New +$91K ﹤0.01% 444

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's CLRB Position: Q2 2024 in Review

Belvedere Trading sold out of Cellectar Biosciences (CLRB) in Q2 2024, closing a stake of 126 shares — an estimated $15K sold.

Belvedere Trading first reported a position in CLRB in Q1 2024 and held it in 1 quarter. The position peaked at $15K in Q1 2024. 37 funds tracked by Wall St. Rank hold CLRB as of Q2 2024.

  • Belvedere Trading reported no remaining Cellectar Biosciences position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 126 Cellectar Biosciences shares in Q2 2024, an estimated $15K.
  • Belvedere Trading first reported a position in Cellectar Biosciences in Q1 2024 and held it in 1 quarter.
  • Belvedere Trading's Cellectar Biosciences position peaked at $15K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.